

Mariana Chavez-MacGregor

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/5836172/mariana-chavez-macgregor-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108
papers

5,279
citations

34
h-index

71
g-index

117
ext. papers

6,366
ext. citations

5.7
avg, IF

5.47
L-index

#	Paper	IF	Citations
108	Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1072-8	2.2	430
107	Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2645-52	2.2	339
106	Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1507-15	2.2	302
105	Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. <i>Annals of Surgical Oncology</i> , 2014 , 21, 704-16	3.1	259
104	Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 553-64	4	253
103	Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , 2010 , 11, 421-8	21.7	227
102	Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 735-44	2.2	181
101	Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016 , 2, 322-9	13.4	177
100	Trastuzumab-related cardiotoxicity among older patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4222-8	2.2	162
99	Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. <i>Lancet Oncology, The</i> , 2014 , 15, e625-e634	21.7	141
98	Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4040-4046	2.2	133
97	Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3801-3810	3.1	123
96	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. <i>JAMA Oncology</i> , 2018 , 4, 203-209	13.4	110
95	Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2628-34	2.2	102
94	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. <i>JAMA Oncology</i> , 2017 , 3, 509-515	13.4	97
93	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2433-2443	2.2	95
92	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018 , 267, 946-951	7.8	94

91	Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. <i>Practical Radiation Oncology</i> , 2016 , 6, 287-295	2.8	92
90	cMET and phospho-cMET protein levels in breast cancers and survival outcomes. <i>Clinical Cancer Research</i> , 2012 , 18, 2269-77	12.9	86
89	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2239-45	3.2	78
88	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019 , 21, 78	8.3	75
87	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. <i>JAMA Oncology</i> , 2016 , 2, 929-36	13.4	73
86	Male breast cancer according to tumor subtype and race: a population-based study. <i>Cancer</i> , 2013 , 119, 1611-7	6.4	71
85	Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2176-83	2.2	70
84	Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. <i>JACC: Cardiovascular Imaging</i> , 2018 , 11, 1084-1093	8.4	56
83	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. <i>Oncologist</i> , 2017 , 22, 1292-1300	5.7	56
82	Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. <i>Clinical Breast Cancer</i> , 2011 , 11, 325-31	3	56
81	Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016 , 23, 1515-21	3.1	53
80	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 407-16	4.4	50
79	Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. <i>Cancer</i> , 2013 , 119, 7-15	6.4	43
78	Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3501-3509	3.1	41
77	Postmenopausal breast cancer risk and cumulative number of menstrual cycles. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 799-804	4	39
76	Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3502-3509	3.1	34
75	Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. <i>Cancer</i> , 2010 , 116, 4168-77	6.4	32
74	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017 , 61, 53-60	14.4	31

73	Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. <i>Journal of Cancer</i> , 2013 , 4, 549-56	4.5	29
72	Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: A case-control analysis. <i>Breast Cancer Research and Treatment</i> , 2006 , 95, 147-52	4.4	29
71	The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. <i>Regional Anesthesia and Pain Medicine</i> , 2016 , 41, 696-703	3.4	29
70	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018 , 23, 1300-1309	5.7	28
69	Angiogenesis in the bone marrow of patients with breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 5396-400	6.4	28
68	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 685-693	2.2	28
67	Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. <i>Clinical Breast Cancer</i> , 2015 , 15, 153-60	3	27
66	Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 90-5	3.1	27
65	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015 , 6, 2604-14	3.3	27
64	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 713-21	1.9	26
63	Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 101-12	4.4	25
62	Mesothelin expression and survival outcomes in triple receptor negative breast cancer. <i>Clinical Breast Cancer</i> , 2013 , 13, 378-84	3	24
61	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	23
60	Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. <i>Cancer</i> , 2018 , 124, 679-687	6.4	23
59	Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2016 , 24, 3557-65	3.9	22
58	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019 , 37, 345-351	4.3	20
57	Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. <i>SpringerPlus</i> , 2013 , 2, 409		19
56	DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. <i>Journal of Cancer</i> , 2017 , 8, 2653-2662	4.5	19

55	Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. <i>Cancer</i> , 2016 , 122, 3447-3455	6.4	19
54	Ductal Carcinoma In Situ and Margins . <i>Annals of Surgery</i> , 2019 , 269, 150-157	7.8	19
53	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , 2017 , 123, 2422-2431	6.4	18
52	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016 , 7, 76362-76373	3.3	18
51	Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. <i>Cancer</i> , 2018 , 124, 899-906	6.4	18
50	Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgery</i> , 2017 , 265, 574-580	7.8	17
49	Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 367-74	4.4	17
48	Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 417-23	4.4	16
47	Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 316-23	4	16
46	Barriers to the Use of Breast Cancer Risk Reduction Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 927-35	7.3	16
45	Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. <i>Cancer</i> , 2011 , 117, 3641-9	6.4	16
44	Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. <i>Cancer</i> , 2017 , 123, 940-947	6.4	15
43	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , 2017 , 116, 509-514	8.7	14
42	Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2730-2737	3.1	14
41	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015 , 6, 310-8	4.5	14
40	Breast cancer, neoadjuvant chemotherapy and residual disease. <i>Clinical and Translational Oncology</i> , 2010 , 12, 461-7	3.6	14
39	Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review. <i>Drugs and Aging</i> , 2019 , 36, 341-354	4.7	13
38	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017 , 123, 3367-3376	6.4	12

37	American Society of Breast Surgeons Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2965-2974	3.1	12
36	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020 , 15, e0229903	3.7	11
35	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3938-3958	2.2	11
34	Everolimus in the treatment of hormone receptor-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1835-43	5.9	10
33	Breast cancer in 2012: New drugs, new knowledge, new targets. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 75-6	19.4	9
32	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016 , 21, 217	5.7	9
31	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020 , 25, 749-757	5.7	8
30	Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. <i>Cancer</i> , 2012 , 118, 326-32	6.4	8
29	Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. <i>Cancer</i> , 2018 , 124, 1760-1769	6.4	7
28	Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. <i>Academic Radiology</i> , 2017 , 24, 191-199	4.3	6
27	Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. <i>Clinical Neurology and Neurosurgery</i> , 2018 , 173, 61-64	2	6
26	Delayed initiation of adjuvant chemotherapy in older women with breast cancer. <i>Cancer Medicine</i> , 2020 , 9, 6961-6971	4.8	6
25	Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 339-350	4.4	6
24	ASCO Resource-Stratified Guidelines: Methods and Opportunities. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	6
23	Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. <i>Cancer</i> , 2020 , 126, 3929-3938	6.4	5
22	Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. <i>Supportive Care in Cancer</i> , 2016 , 24, 2693-706	3.9	5
21	Two birds with one stone: octreotide treatment for acromegaly and breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, e398-400	2.2	5
20	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR, HER2 Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6417-6428	12.9	5

19	Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. <i>Biomarkers in Medicine</i> , 2016 , 10, 315-28	2.3	4
18	Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. <i>Current Breast Cancer Reports</i> , 2018 , 10, 296-306	0.8	4
17	Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2229-2237	3.1	4
16	Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2020 , 25, 937-942	5.7	3
15	Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020 , 27, 359-366	3.1	3
14	Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage: An Analysis of Use of Radiation Therapy After Breast-Conserving Surgery. <i>JAMA Oncology</i> , 2017 , 3, 1425-1426 ^{1,2}	13.4	2
13	Tamoxifen therapy for patients with breast cancer. <i>Lancet, The</i> , 2013 , 381, 2077-8	4.0	2
12	The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa-Maternal Orphans and a Cycle of Disadvantage. <i>JAMA Oncology</i> , 2021 , 7, 197-198	13.4	2
11	Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. <i>Cancer</i> , 2018 , 124, 4685-4691	6.4	2
10	Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2021 , 1	3.1	2
9	Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms. <i>Cancer</i> , 2020 , 126, 3456-3463	6.4	2
8	Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. <i>Lancet Oncology, The</i> , 2017 , 18, 1568-1569	21.7	1
7	Use of Biosimilar Medications in Oncology.. <i>JCO Oncology Practice</i> , 2022 , OP2100771	2.3	1
6	Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy?. <i>Plastic and Reconstructive Surgery</i> , 2020 , 146, 945-953	2.7	1
5	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 637-44	4	1
4	A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. <i>Oncologist</i> , 2021 , 26, e230-e240 ¹	5.7	1
3	Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021 , 28, 3703-3713	3.1	0
2	Movement Through Chemotherapy Delay to Initiation Among Breast Cancer Patients: A Qualitative Analysis.. <i>Patient Preference and Adherence</i> , 2022 , 16, 749-759	2.4	0

- 1 Adjuvant bisphosphonates in breast cancer: has the time come?. *Breast Cancer Management*, **2013**, 2, 327-337 0.7